Connected sensor technologies and tools, from wearables, smart speakers, and bed mats to ingestible sensing capsules and implantables, are capturing unprecedented flows of data with the potential to transform our clinical decision making. Since DiMe’s launch in October 2019, there has been a 929% increase in the number of digital endpoints being used by the life sciences industry for the safety and efficacy of new drug development. Yet we remain unprepared to access reliable and trustworthy sensor data at scale.
